AgingResearch.NewsJoin free

Zhejiang DTRM Biopharma

CompanyChina

Zhejiang DTRM Biopharma develops one asset, approved (everolimus in advanced breast cancer). Mostly small molecule acting on autophagy, mTOR signalling and MTOR; based in China.

1
Asset
Furthest
Approved
1
Trial
0
Signals

Pipeline

1

  • everolimus

    Inhibits mTORC1 through FKBP12 binding, suppressing cell growth and promoting autophagy.

    Approved, Small molecule, Autophagy, mTOR signalling, advanced breast cancer, Angiomyolipoma

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms4
  • Trials1
  • Similar companies6

Updated 12 Oct 2026 · 104 sources

Intelligence